Altered subcortical emotional salience processing differentiates Parkinson's patients with and without psychotic symptoms.
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
10
2019
revised:
30
03
2020
accepted:
05
05
2020
pubmed:
17
6
2020
medline:
9
3
2021
entrez:
17
6
2020
Statut:
ppublish
Résumé
Current research does not provide a clear explanation for why some patients with Parkinson's Disease (PD) develop psychotic symptoms. The 'aberrant salience hypothesis' of psychosis has been influential and proposes that dopaminergic dysregulation leads to inappropriate attribution of salience to irrelevant/non-informative stimuli, facilitating the formation of hallucinations and delusions. The aim of this study is to investigate whether non-motivational salience is altered in PD patients and possibly linked to the development of psychotic symptoms. We investigated salience processing in 14 PD patients with psychotic symptoms, 23 PD patients without psychotic symptoms and 19 healthy controls. All patients were on dopaminergic medication for their PD. We examined emotional salience using a visual oddball fMRI paradigm that has been used to investigate early stages of schizophrenia spectrum psychosis, controlling for resting cerebral blood flow as assessed with arterial spin labelling fMRI. We found significant differences between patient groups in brain responses to emotional salience. PD patients with psychotic symptoms had enhanced brain responses in the striatum, dopaminergic midbrain, hippocampus and amygdala compared to patients without psychotic symptoms. PD patients with psychotic symptoms showed significant correlations between the levels of dopaminergic drugs they were taking and BOLD signalling, as well as psychotic symptom scores. Our study suggests that enhanced signalling in the striatum, dopaminergic midbrain, the hippocampus and amygdala is associated with the development of psychotic symptoms in PD, in line with that proposed in the 'aberrant salience hypothesis' of psychosis in schizophrenia.
Identifiants
pubmed: 32540629
pii: S2213-1582(20)30114-5
doi: 10.1016/j.nicl.2020.102277
pmc: PMC7298672
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102277Subventions
Organisme : Medical Research Council
ID : G0701911
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Neurobiol Aging. 2009 Nov;30(11):1737-48
pubmed: 18325636
Mov Disord. 2012 Aug;27(9):1137-45
pubmed: 22821557
Brain. 2000 Apr;123 ( Pt 4):733-45
pubmed: 10734005
J Neurol Sci. 2010 Feb 15;289(1-2):12-7
pubmed: 19740486
Schizophr Bull. 2007 Jul;33(4):971-81
pubmed: 17519393
Acta Neuropathol. 2000 Sep;100(3):285-90
pubmed: 10965798
Neuron. 2005 Jun 2;46(5):703-13
pubmed: 15924857
Neurology. 2005 Apr 26;64(8):1404-10
pubmed: 15851731
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):533-5
pubmed: 9576549
CNS Spectr. 2018 Dec;23(6):347-351
pubmed: 28264738
Mol Psychiatry. 2008 Mar;13(3):239, 267-76
pubmed: 17684497
Neuropsychopharmacology. 2018 Jul;43(8):1691-1699
pubmed: 29748629
Neuroimage. 2014 Oct 15;100:580-9
pubmed: 24979343
Parkinsonism Relat Disord. 2010 Nov;16(9):553-60
pubmed: 20538500
Neurosci Lett. 2012 Aug 22;524(1):55-9
pubmed: 22813979
Br J Psychiatry. 2013 Nov;203(5):327-33
pubmed: 24187067
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Nat Rev Neurol. 2017 Feb;13(2):81-95
pubmed: 28106066
Am J Geriatr Psychiatry. 2012 Feb;20(2):123-32
pubmed: 21617521
J Neurol. 2015 Jul;262(7):1780-90
pubmed: 25761375
Clin Neuropharmacol. 2005 Sep-Oct;28(5):228-37
pubmed: 16239763
Am J Psychiatry. 2003 Jan;160(1):13-23
pubmed: 12505794
Arch Neurol. 1999 May;56(5):595-601
pubmed: 10328255
Prog Brain Res. 2008;171:559-62
pubmed: 18718353
Schizophr Bull. 2013 Nov;39(6):1328-36
pubmed: 23236077
Cereb Cortex. 2001 Dec;11(12):1136-43
pubmed: 11709484
J Clin Psychopharmacol. 2013 Apr;33(2):149-51
pubmed: 23422379
Schizophr Bull. 2020 Apr 10;46(3):670-679
pubmed: 32227226
Neurol Sci. 2014 Oct;35(10):1603-5
pubmed: 25012755
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Psychiatry Res. 1991 Aug;38(2):143-62
pubmed: 1754629
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):76-82
pubmed: 21836035
Magn Reson Med. 2003 Sep;50(3):599-607
pubmed: 12939768
Brain. 1985 Mar;108 ( Pt 1):171-91
pubmed: 3978397
Acta Neuropathol. 2003 Jul;106(1):83-8
pubmed: 12687392
Neuroreport. 2010 Dec 29;21(18):1172-6
pubmed: 21057339
J Abnorm Psychol. 2010 Feb;119(1):40-9
pubmed: 20141241
Eur Psychiatry. 2002 Mar;17(1):9-16
pubmed: 11918987
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
J Psychosom Res. 2017 Sep;100:65-76
pubmed: 28789795
Arch Neurol. 2010 Aug;67(8):996-1001
pubmed: 20697051
Mov Disord. 2012 Nov;27(13):1679-82
pubmed: 23150469
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
Drugs Aging. 2008;25(8):665-82
pubmed: 18665659
Radiology. 2005 Apr;235(1):218-28
pubmed: 15716390
Int J Geriatr Psychiatry. 2013 Jun;28(6):626-31
pubmed: 22927195
Cereb Cortex. 2007 Dec;17(12):2940-8
pubmed: 17383999
Mov Disord. 2012 Feb;27(2):186-99
pubmed: 22162004
Neuroimage. 2015 Aug 1;116:158-67
pubmed: 25862267
J Abnorm Psychol. 2005 Aug;114(3):373-384
pubmed: 16117574
Transl Psychiatry. 2018 Sep 21;8(1):196
pubmed: 30242202
Front Neurol. 2017 Apr 24;8:156
pubmed: 28484422
Neuropsychologia. 2016 May;85:19-23
pubmed: 26956927
Drugs. 2016 Jul;76(11):1093-118
pubmed: 27312429
Neuron. 2006 Aug 3;51(3):369-79
pubmed: 16880131
Neurobiol Dis. 2012 Jun;46(3):581-9
pubmed: 22245219
Neuropsychopharmacology. 2012 Mar;37(4):950-8
pubmed: 22089321
J Neurosci. 2007 Oct 17;27(42):11424-30
pubmed: 17942737
Neuroimage. 2009 May 15;46(1):12-22
pubmed: 19457381
Psychosomatics. 1995 May-Jun;36(3):267-75
pubmed: 7638314